WBI Investments LLC Acquires New Position in DexCom, Inc. (NASDAQ:DXCM)

WBI Investments LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the first quarter, Holdings Channel.com reports. The firm bought 2,177 shares of the medical device company’s stock, valued at approximately $302,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Toroso Investments LLC boosted its position in shares of DexCom by 25.2% in the third quarter. Toroso Investments LLC now owns 15,560 shares of the medical device company’s stock valued at $1,452,000 after acquiring an additional 3,127 shares during the period. Kampmann Melissa S. bought a new position in DexCom in the 3rd quarter valued at $3,538,000. Graham Capital Management L.P. purchased a new position in shares of DexCom during the 3rd quarter valued at $2,346,000. Public Sector Pension Investment Board increased its holdings in shares of DexCom by 12.2% in the third quarter. Public Sector Pension Investment Board now owns 41,644 shares of the medical device company’s stock worth $3,885,000 after purchasing an additional 4,525 shares during the period. Finally, Banque Pictet & Cie SA raised its position in shares of DexCom by 77.8% in the third quarter. Banque Pictet & Cie SA now owns 173,294 shares of the medical device company’s stock worth $16,168,000 after buying an additional 75,848 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on DXCM. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Canaccord Genuity Group raised their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Raymond James increased their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. Redburn Atlantic started coverage on DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 target price for the company. Finally, Citigroup upped their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $140.33.

Insider Buying and Selling at DexCom

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at $5,839,974.37. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction on Friday, May 31st. The shares were sold at an average price of $119.24, for a total value of $77,744.48. Following the transaction, the executive vice president now owns 67,560 shares in the company, valued at $8,055,854.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,102 shares of company stock worth $755,103. Insiders own 0.30% of the company’s stock.

DexCom Stock Up 2.3 %

DexCom stock traded up $2.58 during mid-day trading on Thursday, hitting $113.37. The company had a trading volume of 1,088,363 shares, compared to its average volume of 2,881,725. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The stock’s 50 day moving average price is $120.10 and its two-hundred day moving average price is $125.12. The company has a market capitalization of $45.08 billion, a PE ratio of 71.48, a price-to-earnings-growth ratio of 2.71 and a beta of 1.16. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. As a group, sell-side analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.